Clinical Research Bibliography: Psilocybin-assisted psychotherapy

Updated August 10, 2018

 

Section A: Original research papers directly supporting psilocybin in treatment of end-of-life distress.

 

Malone T, Mennenga S, … Bossis A, et al. (April 2018) Individual Experiences in Four
Cancer Patients Following Psilocybin-Assisted Psychotherapy. Frontiers in Pharmacology 9:256. doi: 10.3389/fphar.2018.00256

 

Swift T, Belser A, … Bossis A, et al. (June 2017) Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. Journal of Humanistic Psychology 57(1):002216781771596 doi: 10.1177/0022167817715966

 

Belser A, Agin-Liebes G, Bossis A, et al. (April 2017) Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. Journal of Humanistic Psychology 57(4): 354-388. doi: 10.1177/0022167817706884

 

Ross S, Bossis A, Guss J, et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Psychopharmacology 30: 1165-1180. doi:10.1177/026988111667551

 

Griffiths R, Johnson M, Carducci M, Umbricht A, Richards W, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacology 30: 1181-1197. doi:10.1177/0269881116675513

These two articles are supplemented by important professional commentary that accompanies them: http://journals.sagepub.com/toc/jopa/30/12

 

Grob C, Danforth A, Chopra G, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68: 71-78.

 

Grob, C. (2007) The use of psilocybin in patients with advanced cancer and existential anxiety. In Psychedelic medicine: new evidence for hallucinogenic substances as treatments, Vol. 1. Ed. M. Winkelman and T.B. Roberts, 205-216. Westport: Praeger

 

Section B: Articles summarizing and supporting recent research into use of psilocybin in treatment of end-of-life anxiety & depression.

 

Reiche S, Hermle L, Gutwinski S. (2017) Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry doi:10.1016/j.pnpbp.2017.09.012

 

Nutt D. (2016) Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology Vol. 30(12) 1163–1164.

Mithoefer M, Grob C, Brewerton T. (2016) Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry.

 

Tupper K, Wood E, Yensen R, et al. (2015) Psychedelic medicine: a re-emerging therapeutic paradigm. Canadian Medical Association Journal.

 

Grob C, Bossis A, Griffiths R. (2013) Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In Psychological Aspects of Cancer, B.I. Carr and J. Steel (eds.): 291-308

 

Griffiths R, Grob C. (2010) Hallucinogens as medicine. Sci. Am. 303, 76–79.

 

Section C: Original research papers indirectly supporting psilocybin treatment for end-of-life distress.

 

Carhart-Harris R, Leech R, Williams T, et al. (2012) Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. The British Journal of Psychiatry 200, 238–244.

Griffiths R, Johnson M, Richards W, et al. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218(4): 649-665

 

MacLean L, Johnson M, Griffiths R. (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology 0(0) 1-9

 

Griffiths R, Richards W, Johnson M, et al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology 22(6): 621-632.

 

Griffiths R, Richards W, McCann U, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187: 268-83.

 

Section D: original research papers: LSD in treatment of end-of-life anxiety & depression. These papers are included as relevant because LSD has subjective effects similar to psilocybin.

 

Gasser P, Holstein D, Michel Y, et al. March (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease 202: 513-520

Gasser P, Kirchner K, Passie T. (2014) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of sustained subjective effects. Journal of Psychopharmacology: 1-12

 

Grof S, Goodman L, Richards W, et al. (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int. Pharmacopsychiatry 8: 129-144.

 

Section E: Original research papers: psilocybin in treatment of other psychiatric disorders: depression, alcohol dependence, tobacco addiction, & obsessive-compulsive disorder.

 

Carhart-Harris R, Bolstridge M, Rucker J, et al. (May 2016) Psilocybin with psychological support for treatment-resistant depression: an open label feasibility study. Lancet Psychiatry.

Bogenschutz M, Forcehimes A, Pommy J, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 1-11

Johnson M, Garcia-Romeu A, Cosimano M, et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacology published online September 2014.

Moreno F, Wiegand C, Taitano E, et al. (2006) Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder. J Clinical Psychiatry 67:1735–1740.

 

Section F: Subjective effects of psilocybin in healthy humans.

 

Studerus E, Kometer M, Hasler F, Vollenweider F. (2011) Acute, sub-acute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology 25(11) 1434–1452

Section G: Clinical safety aspects

 

Johnson M, Griffiths R, et al. (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Journal of Neuropharmacology, https://doi.org/10.1016/j.neuropharm.2018.05.012

Carbonaro T, Bradstreet M, Barrett F, et al. (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology December 30: 1268-1278, first published on August 30, 2016 doi:10.1177/0269881116662634

 

Hendricks P, Johnson M, Griffiths R. (2015) Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology, Vol. 29(9) 1041–1043

Johnson M, Richards W, Griffiths R. (2008) Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology 22(6): 603-620.

 

Richards W. (2004) Navigation within consciousness: insights from four decades of psychotherapy research with imagery, music, and entheogens. Journal of the Association for Music and Imagery (2003-2004), Vol. 9

ALL ARTICLES ON THIS BIBLIOGRAPHY ARE AVAILABLE ONLINE WITHOUT CHARGE